Clinical Trial

Intratumoral CAN2109 in Subjects With Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 19, 2024 (before its estimated May 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
A phase 1, dose escalation, open-label study of intratumoral CAN2109 in subjects with unstable or metastatic advanced solid tumors or lymphomas.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-03-20; most recent amendment 2024-12-16.
Status change: Not Yet Recruiting → Recruiting 2024-10-29
Trial Details
NCT Number NCT06332430
Lead Sponsor Canwell Biotech Limited
Conditions Solid Tumor, Lymphoma
Enrollment 27 participants
Start Date 2024-05-28
Primary Completion 2025-05-30 (estimated)
Study Completion 2026-05-30 (estimated)
Updated on ClinicalTrials.gov 2024-12-19